Phaseline

Companies › Veru

Veru: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Enobosarm
Androgen Receptor modulator
ARPhase 2Obesity & OverweightOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07446998EnobosarmPhase 2Obesity & OverweightMetabolic and endocrineOct 2027

From the company's SEC filings

Cash of $24m on 2026-06-30; operating cash outflow about $28m a year; runway about 10 months at that burn, to May 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

AR (1)

Companies with the same targets

Johnson & Johnson (Janssen) Novartis Astellas Alessa Therapeutics Sun Pharmaceutical Industries Hansoh BioMedical R&D Company Merck & Co. (MSD) Bayer Qilu Pharmaceutical Aragon Pharmaceuticals

Companies built like this

Skye Bioscience Actimed Therapeutics PolTREG Protalix Verdiva Bio Dev

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.